Stay updated with breaking news from Nasdaq Xlo. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Xilio Therapeutics, Inc. (NASDAQ:XLO – Get Free Report) was the target of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 379,500 shares, an increase of 600.2% from the March 31st total of 54,200 shares. Based on an average trading volume of 1,170,000 shares, […]
Xilio Therapeutics, Inc. (NASDAQ:XLO – Get Free Report) major shareholder Gilead Sciences, Inc. acquired 485,250 shares of the business’s stock in a transaction dated Tuesday, April 2nd. The stock was purchased at an average price of $0.76 per share, for a total transaction of $368,790.00. Following the completion of the acquisition, the insider now owns […]
Xilio Therapeutics, Inc. (NASDAQ:XLO – Get Free Report) was the target of a large growth in short interest in the month of January. As of January 15th, there was short interest totalling 6,500 shares, a growth of 364.3% from the December 31st total of 1,400 shares. Based on an average trading volume of 152,100 shares, […]
WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and...
Xilio Therapeutics, Inc. (NASDAQ:XLO – Free Report) – Investment analysts at Chardan Capital issued their FY2023 earnings estimates for Xilio Therapeutics in a research note issued to investors on Monday, July 10th. Chardan Capital analyst M. Barcus expects that the company will post earnings of ($3.22) per share for the year. Chardan Capital has a […]